confidio®
Pharmacy solutions you can trust.

3RD QUARTER 2021 PIPELINE REPORT:
MEDICAL AND PHARMACY BENEFIT DRUGS

This Pipeline Report is focused on potentially budget-busting medications. We bring you information on

- What these drugs are used for;
- How common those conditions are;
- Current treatments for those conditions;
- How much the current treatments cost; and
- What to expect when these drugs have been approved.

Most importantly, as a trusted advisor, Confidio recommends viable strategies for managing these expensive treatments.

There are three sections in this report:

- **Top Five:** our pick of products recently approved or pending approval that we believe warrant the most attention
- **Recent FDA Approvals:** detailed information on recently approved high-cost drugs under both the medical and pharmacy benefit
- **Anticipated Approvals:** summary table for potentially high-cost products under development

TOP FIVE:

Recently approved or pending approval products that may have a significant impact on drug costs in the medical or pharmacy benefit.

WHAT *Drug & condition*	**WHEN** *FDA approval date*	**WHERE** *Probable benefit coverage*	**WHY** *What earned this drug a Top 5 placement*	**HOW** *Strategies for managing cost*
vosoritide For the treatment of achondroplasia, the most common type of dwarfism (genetic)	Anticipated approval, August 2021	Pharmacy benefit	• While this product's indication is extremely rare, it would revolutionize treatment of this condition, likely commanding a premium price. • Orphan drug, Priority Review	• Prior authorization to ensure member has the indicated type of dwarfism • Patient support groups • Member inventory management (MIM) • Education
Aduhelm (aducanumab) For the treatment of Alzheimer's disease (AD)	Approved June 7, 2021	Medical benefit	• High incidence* of this devastating disease (1.5 cases per 1,000 population) • Questions about effectiveness noted by FDA advisory board and ICER • May see high volume (patient, caregiver demand) • First potentially disease modifying treatment • High cost plus need for high volume of sites, specialists and costly tests could decimate budgets	• Prior authorization to ensure appropriate patient selection • Evaluate options for clinically appropriate, least costly site of care
toripalimab For the treatment of nasopharyngeal (nose and throat) cancer	Anticipated approval, July 2021	Medical benefit	• Although nasopharyngeal cancer is relatively rare, this drug also has fast-track status for mucosal melanoma (rare but very poor prognosis) and is showing promise in liver cancer (poor prognosis and more common at 1 case per 100,000 population). Cancer drugs are often used for non-approved indications. • Current FDA designations - Breakthrough Therapy, Orphan Drug, Fast track	• Prior authorization to ensure use for FDA approved or compendia-endorsed indication(s) • Evaluate options for clinically appropriate, least costly site of care

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

TOP FIVE *(continued)*:

Recently approved or pending approval products that may have a significant impact on drug costs in the medical or pharmacy benefit.

WHAT *Drug & condition*	**WHEN** *FDA approval date*	**WHERE** *Probable benefit coverage*	**WHY** *What earned this drug a Top 5 placement*	**ACTIONS** *Strategies for managing cost*
teplizumab For the prevention or delay of type 1 diabetes	Anticipated approval, July 2021	Medical benefit	• Prevention of destruction of insulin-producing cells would make this the first disease-modifying therapy ever for type 1 diabetes • FDA Breakthrough Therapy and Priority Review designation • About 5-10% of people with diabetes have type 1 diabetes, so its prevalence* is about 50 cases per 10,000 population	• Prior authorization to prevent use for type 2 diabetes and for appropriate patient selection • Education
reltecimod For organ dysfunction/ failure caused by "flesh-eating" bacteria (necrotizing soft tissue infections aka NSTIs)	Anticipated approval, September 2021	Medical benefit	• Novel mechanism: modulates the immune overreaction responsible for organ and tissue damage (not an antibiotic) • Will not promote bacterial resistance • Current FDA designations - Fast Track, Orphan Drug, Accelerated Approval	• Prior authorization to ensure organ dysfunction/ failure are present or suspected • Complex case management

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS

Pharmacy Benefit

Empaveli (pegcetacoplan): Apellis

- **Approval date: 5/14/2021**
- **Pharmacy benefit**
  - Administered subcutaneously
  - Available only through a Risk Evaluation and Mitigation Strategy (REMS) program
- **Indication and frequency**
  - Paroxysmal nocturnal hemoglobinuria (PNH)(blood disease where immune cells attack red blood cells causing anemia)
  - Prevalence*: 5,000-6,000 cases in the US
- **Cost factors**
  - $458,000 annually
  - Therapeutic alternative annual treatment cost: Soliris (eculizumab) @ $522K annually or Ultomiris (ravulizumab cwvz) @ $459K
- **Therapeutic impact**
  - Major advance
    - Fast Track, Priority Review, Orphan Drug
    - Unique mechanism that has shown significantly better results than Soliris in a head-to-head study; Ultomiris has a mechanism similar to Soliris
    - Carries a black box warning due to increased risk of infection
    - Low disease prevalence and competitive pricing suggest that impact on plan budgets will not be great
- **Management strategies**
  - Inquire into PBM programs
  - Prior authorization to confirm diagnosis
  - Copay assistance may be available through ApellisAssist
  - Home inventory management

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Pharmacy Benefit

Lumakras (sotorasib): Amgen

- **Approval date: 5/28/2021**
- **Pharmacy benefit**
  - Administered orally once daily
- **Indication and frequency**
  Lung cancer (non-small cell lung cancer with KRAS G12C genetic mutation, locally advanced or metastatic, in patients who have tried at least one other systemic therapy): incidence* 8 cases per 100,000 population
- **Cost factors**
  - Annual cost: $217,774
  - Therapeutic alternative annual treatment cost: Keytruda (pembrolizumab) + cisplatin + Alimta (pemetrexed) at $227,000
- **Therapeutic impact**
  - Major advance
    - FDA Real-Time Oncology Review pilot program and accelerated approval pathway
    - Continued approval contingent upon confirmatory trials for clinical benefit
    - First product to target this particular genetic mutation
    - Before this product, patients had poor prognosis, few treatment alternatives
- **Management strategies**
  - Prior authorization to ensure trial/failure of first-line therapies and confirmation of KRAS G12C genetic mutation
  - 10 week prior authorization approval duration
  - Copay assistance may be available through Amgen First Step program
  - Split fill program

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Pharmacy Benefit

Truseltiq (infigratinib): BridgeBio Pharma, QED Therapeutics

- **Approval date: 5/28/2021**
- **Pharmacy benefit**
  - Administered orally
- **Indication and frequency**
  Often-fatal bile duct cancer (previously treated, unresectable cholangiocarcinoma with FGFR2 gene abnormalities); incidence* < 1 case per 100,000 population
- **Cost factors**
  - $280,265 annually
  - Therapeutic alternative annual treatment cost: no real standard of therapy for this group of patients
- **Therapeutic impact**
  - Incremental improvement
    - FDA Real-Time Oncology Review pilot program and accelerated approval pathway
    - Continued approval contingent upon confirmatory trials for clinical benefit
    - Approved based on a clinical trial where only 23% of patients responded, and only for a median duration of 5 months
- **Management strategies**
  - Inquire into PBM programs
  - Prior authorization to confirm FGFR2 gene abnormalities and unresectable (inoperable) tumor
  - Copay assistance may be available through QED Therapeutics' ForgingBridges program

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Abecma (idecabtagene vicleucel): Bristol-Myers Squibb, Celgene, bluebird bio

- **Approval date: 3/26/2021**
- **Medical benefit**
  - Given as a single lifetime IV infusion
  - Available only through a Risk Evaluation and Mitigation Strategy (REMS) program
  - Limited distribution
- **Indication and frequency**
  Blood cancer (relapsed or refractory multiple myeloma, after 4 or more specific types of therapies); incidence* of myeloma, 1 case per 10,000 population
- **Cost factors**
  - One-time cost, $419,500 (but requires 3 days of chemotherapy prior to infusion at a cost of approximately $1400 total).
  - Therapeutic alternative annual treatment cost: many alternatives, ranging from $170,000 to $350,000 per year
- **Therapeutic impact**
  - Incremental improvement
    - There are numerous alternatives available for patients at this stage of therapy
    - Survival following administration was not as long as initially hoped.
    - Carries several FDA "black box warnings" about significant adverse effects
- **Management strategies**
  - Inquire into PBM programs
  - Prior authorization to confirm failure of previous therapies
  - Copay assistance may be available through CellTherapy360.com
  - Oncology case management
  - Investigate special arrangements such as centers of excellence/ certified healthcare facilities for administration

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Aduhelm (aducanumab): Biogen

- **Approval date:6/7/2021**
- **Medical benefit**
  - Administered as an IV infusion over 1 hour every 4 weeks
- **Indication and frequency**
  Treatment of Alzheimer's disease: incidence* 1.5 cases per 1,000 population
- **Cost factors**
  - $56,000 annually
  - Diagnostic testing requiring collection of cerebral spinal fluid, monitoring through PET scans, and infusion suites will be required (along with specialized staffing); with high volume of users, these could overwhelm national financial and medical provider resources.
  - The bulk of recipients will be Medicare beneficiaries.
  - Therapeutic alternative annual treatment cost: Not applicable; this is the first drug approved for this indication
- **Therapeutic impact**
  - Major advance(with caveats)
    - First approved product to treat the underlying cause of Alzheimer's disease
    - FDA accelerated approval; continued approval contingent upon confirmatory trials for clinical benefit
    - If the product demonstrates clinical benefits, it will be a boon to patients and their caregivers. FDA Advisory Committee, as well as many others, question whether the product provides a meaningful clinical benefit
- **Management strategies**
  - Prior authorization to confirm diagnosis
  - Evaluate options for clinically appropriate, least costly site of care

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Jemperli (dostarlimab-gxly): GlaxoSmithKine

- **Approval date: 4/22/2021**
- **Medical benefit**
  - Administered intravenously over 30 minutes
  - Limited distribution
- **Indication and frequency**
  Cancer of the uterus with a specific genetic defect (refractory or recurrent dMMR endometrial cancer that has progressed on or following preferred treatment): incidence* is about 6 cases per 100,000 population
- **Cost factors**
  - Annual cost: $180,230
  - Therapeutic alternative annual treatment cost: Keytruda (pembrolizumab), $177,660
- **Therapeutic impact**
  - Incremental improvement
    - Is the 7th product in its class; has not been directly compared to other treatments
    - FDA accelerated approval and Priority Review and Breakthrough Therapy designations; but continued approval contingent upon confirmatory trials for safety and efficacy.
- **Management strategies**
  - Inquire into PBM programs
  - Prior authorization to ensure trial/failure of first-line therapies and confirmation of dMMR cell type
  - Copay assistance may be available through GSK Copay Program
  - Oncology case management
  - Evaluate options for clinically appropriate, least costly site of care

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Rybrevant (amivantamab-vmjw): Janssen

- **Approval date: 5/21/2021**
- **Medical benefit**
  - Administered intravenously over 2-5 hours
- **Indication and frequency**
  Lung cancer (metastatic and cisplatin-resistant non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations): incidence* of NSCLC with this type of cell mutations: 1 case per 100,000 population
- **Cost factors**
  - Annual cost: $233,582
  - Therapeutic alternative annual treatment cost: no suitable alternative
- **Therapeutic impact**
  - Major advance
    - First approved option for this subtype of NSCLC.
    - New mechanism of action for this subtype of NSCLC
    - Priority Review, Breakthrough Therapy
    - FDA accelerated approval; continued approval contingent upon confirmatory trials for safety and efficacy
- **Management strategies**
  - Inquire into PBM programs
  - PA to ensure test results confirm EGFR exon 20 insertion mutations, and that cancer has progressed while patient was on or after use of cisplatin
  - Copay assistance may be available through the Janssen CarePath Savings Program
  - Evaluate options for clinically appropriate, least costly site of care

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Ryplazim (plasminogen, human-tvmh): Liminal BioScience

- **Approval date: 6/4/2021**
- **Medical benefit**
  - Administered intravenously at 2-4 day intervals
- **Indication and frequency**
  Enzyme deficiency that results in inflamed growths on mucous membranes and eyes; may cause blindness (congenital plasminogen deficiency): Prevalence is 1.6 cases per 1,000,000 population
- **Cost factors**
  - Annual cost: TBD
  - Therapeutic alternative annual treatment cost: no suitable alternative; current treatment is for symptoms only.
- **Therapeutic impact**
  - Major advance
    - Currently no established approach to treatment.
    - Orphan Drug, Rare Pediatric Disease Priority Review
- **Management strategies**
  - Inquire into PBM programs
  - PA to ensure appropriate diagnosis (may be sought for treatment of idiopathic pulmonary fibrosis) and to require testing to confirm increased trough plasminogen activity by an absolute 10% above baseline before approving renewals
  - Complex case management

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

RECENT FDA APPROVALS *(continued)*

Medical Benefit

Zynlonta (fka Lonca)(loncastuximab tesirine-lpyl): ADC Therapeutics

- **Approval date: 4/23/2021**
- **Medical benefit**
  - Administered intravenously over 30 minutes
- **Indication and frequency**
  Blood cancer (relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy): incidence* 7.5 cases per 100,000 population
- **Cost factors**
  - Annual cost: $234,413
  - Therapeutic alternative annual treatment cost: Yescarta (axicabtagene ciloleucel) or Kymriah (tisagenlecleucel) each at $370,000 or Breyanzi (lisocabtagene maraleucel), $400,000
- **Therapeutic impact**
  - Incremental improvement
    - Fourth drug in its class
    - May bind more strongly to target cells than other drugs in its class, possibly improving effectiveness
    - FDA accelerated approval; continued approval contingent upon confirmatory trials for safety and efficacy
- **Management strategies**
  - Inquire into PBM programs
  - PA to ensure at least 2 lines of previous therapy; but given relative cost, criteria should not be more restrictive than those of Yescarta, Kymriah or Breyanzi
  - Copay assistance may be available through ADVANCING Patient Support Copay Assistance Program
  - Evaluate options for clinically appropriate, least costly site of care

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS

Pharmacy Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement and Route of Administration	Indication/Use	Condition Incidence or Prevalence*	Therapeutic Impact	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
6/17/2021		arimoclomol	Pharmacy--Oral	Niemann-Pick disease type C (rare genetic life-threatening disorder that causes nerve damage)	Incidence* < 1 case per 100,000 live births	• Rare Pediatric Disease • Orphan drug • Breakthrough Therapy • Fast-track	TBD	No alternatives; symptomatic treatment only
2Q2021		tanezumab	Pharmacy--Subcutaneous	Osteoarthritis pain	32.5 million US adults, approximately 10% of US population	• First of this type of treatment for osteoarthritis • Due to risk/ benefit profile, not expected to replace standard pain control measures	TBD	Numerous over-the-counter non-prescription products
7/2021		avacopan	Pharmacy--Oral	ANCA associated vasculitis (rare disorder of blood vessels causing kidney and lung problems)	Incidence* < 1 case per 10,000 population	Unique mechanism of action	TBD	Rituxan @ $19K
8/2021		vosoritide	Pharmacy--Subcutaneous	Achondroplasia, a rare, genetic type of dwarfism	Incidence* 3-5 cases per 100,000 live births	First product to treat condition	TBD	N/A

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS *(continued)*

Pharmacy Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement and Route of Administration	Indication/Use	Condition Incidence or Prevalence*	Therapeutic Impact	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
8/2021		belumosudil	Pharmacy--Oral	Chronic graft versus host disease (cGVHD) (bone marrow/stem cell transplant side effect that can be fatal)	Approximately 9,000 allogeneic transplants were performed in 2018; GVHD occurs in 30% to 60% of such transplants	If approved, will be first FDA-approved drug for cGVHD in patients 12 to 18 years of age	TBD	Imbruvica @ $180K
9/2021		maralixibat	Pharmacy--Oral	Alagille syndrome (bile duct disorder that causes progressive liver damage)	Occurs in one case per 30,000 live births	• Rare Disease • Breakthrough Therapy • Priority Review	TBD	Ursodiol @ $2.8K
10/2021		bimekizumab	Pharmacy--Subcutaneous	Plaque psoriasis (common skin condition)	Incidence* 8 cases per 10,000 population	Multiple products on market with similar mechanism of action	TBD	Remicade @ $25K, Stelara @ $88K, Cosentyx @ $124K and others
10/2021		somatrogon	Pharmacy--Subcutaneous	Pediatric growth hormone deficiency	Incidence* less than 1 case per 10,000 population	Compares to Genotropin/ somatropin, but is dosed once weekly	TBD	Genotropin @ $107K
3Q2021		abrocitinib	Pharmacy--Oral	Atopic dermatitis, moderate to severe (eczema; itchy skin rash)	Prevalence* of moderate to severe AD in the US: 11.7million	• Breakthrough therapy • Priority review • Pecent safety concerns with this drug class	TBD	Dupixent @ $42K

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS *(continued)*

Pharmacy Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement and Route of Administration	Indication/Use	Condition Incidence or Prevalence*	Therapeutic Impact	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
4Q2021		pacritinib	Pharmacy--Oral	Myelofibrosis (bone marrow disorder that causes bleeding due to low platelet count)	Incidence* 1.5 cases per 100,000 population in the US	May have fewer side effects than other drugs in its class	TBD	Jakafi @180K
CRL 3/15/2021		ropeginterferon alfa-2b	Pharmacy--Subcutaneous	Polycythaemia vera (blood cancer where overabundance of red blood cells causes serious blood 'thickening')	Prevalence*: 2 cases per 100,000 population	Early clinical trials show ropeginterferon alfa-2b results in more complete remissions after 3 years vs. Hydrea	TBD	Hydrea @ $888

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS *(continued)*

Medical Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement	Indication/Use	Condition Incidence or Prevalence in US (unless otherwise indicated)*	Comments	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
7/2021		narsoplimab	Medical--Intravenous	Bone marrow/stem cell transplant-associated side effect: thrombotic microangiopathy (TM-TMA) (can cause anemia, bleeding, permanent organ damage or death)	Incidence* 1 case per 1,000,000 population		TBD	Defitelio @ $170K
7/2021		teplizumab	Medical--Intravenous	Prevention or delay of type 1 diabetes	Prevalence* of type 1 diabetes: 50 cases per 10,000 population	• Single treatment, likely over 14 days • Breakthrough Therapy • Priority Review	TBD	No alternatives; symptomatic treatment only
7/2021		toripalimab	Medical--Intravenous	Nasopharyngeal (nose and throat) cancer	Incidence* of < 1 case per 100,000 population	• Breakthrough Therapy • Orphan Drug • Fast track	TBD	Cisplatin + Gemcitabine @ $24K
8/2021		avalglucosidase alfa	Medical--Intravenous	Pompe disease (rare genetic enzyme deficiency damages liver and heart)	Incidence* < 1 case per 10,000 live births		TBD	Lumizyme @ $600K

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS *(continued)*

Medical Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement and Route of Administration	Indication/Use	Condition Incidence or Prevalence*	Therapeutic Impact	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
8/2021		vicineum	Medical--Administered into the bladder	Resistant bladder cancer	Incidence* 2 cases per 10,000 population		TBD	• Keytruda @ $150K or • gemcitabine @ $12K
9/2021		reltecimod	Medical--Intravenous	Organ dysfunction/ failure caused by "flesh-eating" bacteria (necrotizing soft tissue infections aka NSTIs)	Incidence* of approximately 10 cases per 100,000 population	• Novel mechanism • Fast Track • Accelerated Approval	TBD	No alternatives specifically approved for NSTIs; note that NSTIs often require limb amputation
10/2021		tisotumab vedotin	Medical--Intravenous	Metastatic or recurrent cervical cancer (type of uterine cancer)	Incidence* of cervical cancer: 4 cases per 100,000 population	• Accelerated Approval • Priority Review	TBD	Pembrolizumab @ $175K
12/2021		efgartigimod	Medical--Intravenous	Myasthenia gravis (nervous system disorder)	Incidence* < 1 case per 100,000 lives	• Orphan drug • Early access program allows use prior to FDA approval.	TBD	Soliris @ $700K

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

ANTICIPATED FDA APPROVALS *(continued)*

Medical Benefit

Anticipated Approval Date	Brand Name	Generic Name	Anticipated Benefit Placement and Route of Administration	Indication/Use	Condition Incidence or Prevalence*	Therapeutic Impact	New Product Anticipated Annual Cost	Alternative Therapy on Market and Annual Cost
2021		ciltacabtagene autoleucel	Medical--Intravenous	Multiple myeloma (type of blood cancer)	Incidence* is 1 case per 10,000 population	• Rare Disease • Breakthrough Therapy	TBD	• Pepaxto @ $206K • Combination regimens $169K-$355K • Blenrep @ $246K
2021	Lantidra	donislecel	Medical--transplant into Portal vein	Diabetes: Labile (aka brittle) Type 1 diabetes not well controlled with intensive insulin therapy	Prevalence* of labile type 1 diabetes is 2 cases per 10,000 population	FDA Advisory Committee concluded it has "overall favorable benefit-risk profile" for certain people	TBD	Pancreas transplant @ $408K

*Prevalence is the number of people with the condition at any given time. Incidence is the number of new cases per year.

REFERENCES

The above information was assembled from government and clinical resources for knowledge purposes only. Information and drugs were selected by clinicians based on therapy and potential clinical impact without any manufacturer affiliations or conflicts of interest. Approval status, dates, and WAC price are subject to variation. This document should not be exclusively used for decision-making purposes. WAC pricing data should be used for benchmarking purposes only. Prices listed above should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.

1. ACS. (2020, September 4). Key Statistics for Endometrial Cancer. Retrieved from Cancer.org: https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html
2. AIM with Immunotherapy Foundation. (2020, September 4). MSI-H/dMMR Endometrial Cancer. Retrieved from aimwithimmunotherapy.org: aimwithimmunotherapy.org/wp-content/uploads/2018/10/MSI-H_dMMr-Edometrial-Cancer-Final-1.pdf
3. Altieri L, E. M. (2018). Predictors of mucosal melanoma survival in a population-based setting. Journal of the American Academy of Dermatology, 136-142 DOI https://doi.org/10.1016/j.jaad.2018.09.054 https://www.jaad.org/article/S0190-9622(18)32670-7/pdf. Retrieved from www.dermnetnz.org.
4. ALZFORUM. (2020, Last updated, December 23). THERAPEUTICS Aducanumab. Retrieved from alzforum.org: https://www.alzforum.org/therapeutics/aducanumab
5. Alzheimer's Association. (2020, March 10). 2020 Alzheimer's disease facts and figures. Retrieved from alz-journals: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12068
6. American Cancer Society. (2021, May 13). Key Statistics for Nasopharyngeal Cancer. Retrieved from cancer.org: https://www.cancer.org/cancer/nasopharyngeal-cancer/about/key-statistics.html
7. American Diabetes Association. (2021, May 13). Statistics About Diabetes. Retrieved from diabetes.org: https://www.diabetes.org/resources/statistics/statistics-about-diabetes
8. American Liver Foundation. (2021, May 13). Alagille Syndrome. Retrieved from liverfoundation.org: https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/alagille-syndrome/#facts-at-a-glance
9. Amgen. (2020, December 16). Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation. Retrieved from amgen.com: https://www.amgen.com/newsroom/press-releases/2020/12/amgen-submits-sotorasib-new-drug-application-to-u-s--fda-for-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation
10. Amgen. (2021, May 28). Press Release: FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer. Retrieved from Amgen.com: https://www.amgen.com/newsroom/press-releases/2021/05/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12cmutated-locally-advanced-or-metastatic-nonsmall-cell-lung-cancer
11. ASH. (2020, May 1). Ropeginterferon Alfa-2b Leads to More Durable Responses Than Hydroxyurea in PV. Retrieved from ashclinicalnews.org: https://www.ashclinicalnews.org/news/literature-scan/ropeginterferon-alfa-2b-leads-durable-responses-hydroxyurea-pv/
12. Atox Bio. (2020, December 10). Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease"). Retrieved from prnewswire.com: https://www.prnewswire.com/il/news-releases/atox-bio-announces-fda-acceptance-to-file-the-nda-for-reltecimod-to-treat-suspected-organ-dysfunction-or-failure-in-patients-with-necrotizing-soft-tissue-infection-flesh-eating-disease-301190305.html
13. Bektas M, C.-M. C. (2020). Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology . Journal of Managed Care and Specialty Pharmacy, S3-S8.
14. Berenbaum, F., Blanco, F., Guermazi, A., & et.al. (2020). Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis, 800-810.
15. Bieber T, S. E. (2021). Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. New England Journal of Medicine, 1101-1112.
16. Biogen Inc. (2021). FULL PRESCRIBING INFORMATION: Aduhelm. Cambridge MA: Biogen Inc.
17. Biomarin. (2021, May 19). BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. Retrieved from drugs.com: https://www.drugs.com/clinical_trials/biomarin-announces-oral-presentation-endo2021-endocrine-society-s-annual-meeting-data-demonstrating-19313.html
18. Biomarin. (2021, May 19). Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia. Retrieved from investors.biomarin.com: https://investors.biomarin.com/2020-11-02-Food-and-Drug-Administration-Accepts-BioMarins-New-Drug-Application-for-Vosoritide-to-Treat-Children-with-Achondroplasia#:~:text=Vosoritide%20has%20also%20received%20orphan%20drug%20designation%20from,diagnosis%20
19. BioWorld. (2021, March 1). bioworld.com. Retrieved from Oncopeptides sets it newly approved MM therapy in the middle of the pack: https://www.bioworld.com/articles/504168-oncopeptides-sets-it-newly-approved-mm-therapy-in-the-middle-of-the-pack?v=preview
20. BridgeBio Pharma, Inc. (2020, December 1). BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma. Retrieved from Bridgebio.com: https://bridgebio.com/news/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug-application-for-infigratinib-for-the-treatment-of-cholangiocarcinoma
21. Bristol Myers Squibb. (2021, March). Abecma (idecabtagene vicleucel) [package insert]. Retrieved from https://packageinserts.bms.com/pi/pi_abecma.pdf?mkt_tok=ODA5LVZHRy04MzYAAAF8QbxEQnQsn1CiFNElWJ9r83gDyABRSkKA5G-UWpk8erPjLx-d0RayyOC8UA1h6xC350zRy31pfFpfcrMxDyswVsh2w8MCcMdGXxXHI8d_H5ctQ
22. Brittle Diabetes Foundation. (2021, May 13). Brittle Type 1 Diabetes Statistics . Retrieved from bdtype1.com: https://www.bdtype1.com/brittle-type1-statistics
23. Business Wire. (2020, December 31). CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C. Retrieved from businesswire.com: https://www.businesswire.com/news/home/20201231005028/en/CytRx-Issues-Statement-Regarding-U.S.-Regulatory-Review-of-Arimoclomol-for-Niemann-Pick-Disease-Type-C
24. Cancer.net. (2020, May). Lung Cancer - Non-Small Cell: Statistics. Retrieved from Cancer.net: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics
25. Cavazzoni, P. (2021). FDA's Decision to Approve New Treatment for Alzheimer's Disease. Beltsville MD: FDA Center for Drug Evaluation and Research.
26. CDC. (2020, February 27). The Cost of Arthritis in US Adults. Retrieved from cdc.gov: https://www.cdc.gov/arthritis/data_statistics/cost.htm
27. Centers for Disease Control and Prevention. (2021, May 19). What Is Type 1 Diabetes? Retrieved from cdc.gov: https://www.cdc.gov/diabetes/basics/what-is-type-1-diabetes.html
28. Cicalese, L. (2021, January 31). What is the prognosis for hepatocellular carcinoma (HCC)? Retrieved from www.medscape.com: https://www.medscape.com/answers/197319-39201/what-is-the-prognosis-for-hepatocellular-carcinoma-hcc
29. Conti RM, B. A. (2013). Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. Journal of Clinical Oncology, 1134-1139.
30. cti Biopharma. (2021, May 13). Pacritinib. Retrieved from ctibiopharma.com: https://www.ctibiopharma.com/pacritinib/
31. Fang W, H. Y. (2019, June 17). EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. Retrieved from bmccancer.biomedcentral.com: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5820-0#citeas
32. FDA. (2021). FDA Briefing Document BLA 125734 Donislecel. Silver Spring, MD: US Food and Drug Administration.
33. FDA. (2021, May). Prescribing Information: Rybrevant. Retrieved from accessdata.fda.gov: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf?mkt_tok=ODA5LVZHRy04MzYAAAF9PhO8OA1d6Pr34TgRww6QK41tw2mOjnr9GB_5IVZO_cEiHFhFt-DWj-0E2-i6Lp5G74sy46vtnMKXrHkq2s8LV5Z7Yf7OAJLe9_7pOMXXxrdJ
34. Formulary Decisions. (2020, March 6). Snapshot Bimekizumab. Retrieved from formularydecisions.com: https://www.formularydecisions.com/module/module_generic.aspx?ModuleID=4100&DrugID=7909&CTRL=Details&EvidenceLibraryID=13981&From=Formulary
35. Formulary Decisions. (2020, July 17). Snapshot Efgartigimod. Retrieved from formularydecisions.com: https://www.formularydecisions.com/module/module_generic.aspx?ModuleID=4100&DrugID=8134&CTRL=Details&EvidenceLibraryID=14329&From=Formulary
36. Formulary Decisions. (2020, February 17). Snapshot Narsoplimab. Retrieved from formularydecisions.com: https://www.formularydecisions.com/module/module_generic.aspx?ModuleID=4100&DrugID=7834&CTRL=Details&EvidenceLibraryID=14799&From=Formulary
37. Formulary Decisions. (2021, February 1). Snapshot Avacopan. Retrieved from formularydecisions.com: https://www.formularydecisions.com/module/module_generic.aspx?ModuleID=4100&DrugID=8422&CTRL=Details&EvidenceLibraryID=14758&From=Formulary
38. Formulary Decisions. (2021, January 11). Snapshot Vosoritide (BMN 111). Retrieved from formularydecisions.com: https://www.formularydecisions.com/module/module_generic.aspx?ModuleID=4100&DrugID=8747&CTRL=Details&EvidenceLibraryID=14732&From=Formulary
39. Genetic and Rare Diseases Information Center. (2021, May 17). Type 1 plasminogen deficiency. Retrieved from rarediseases.info.nih.gov: https://rarediseases.info.nih.gov/diseases/4380/type-1-plasminogen-deficiency
40. Hong-McAtee, I. (2014). Growth Hormone Deficiency: A Guide for Families. American Academy of Pediatrics and Pediatric Endocrine Society.
41. IPD Analytics. (2020, October 23). IPD Analytics Market Forecast: Outlook for Tanezumab. Bay Harbor Islands, FL, USA.
42. IPD Analytics. (2020, December 16). Oncology: Diffuse Large B-cell Lymphoma. Retrieved from ipdanalytics.com: https://secure.ipdanalytics.com/User/Pharma/RxStrategy/Page/22873d30-b997-436c-80f3-e2b653d25317
43. IPD Analytics. (2020). Potential High-Cost Drug Approvals Expected Through 2021. Bay Harbor Islands, FL: IPD Analytics.
44. IPD Analytics. (2021, May 17). IPD Analytics Pharmacy & Therapeutics Watch List | 05.17.2021: Apellis' Empaveli Approved for Paroxysmal Nocturnal Hemoglobinuria . Bay Harbor Islands, FL, USA.

REFERENCES *(continued)*

The above information was assembled from government and clinical resources for knowledge purposes only. Information and drugs were selected by clinicians based on therapy and potential clinical impact without any manufacture affiliations or conflicts of interest. Approval status, dates, and WAC price are subject to variation. This document should not be exclusively used for decision-making purposes. WAC pricing data should be used for benchmarking purposes only. Prices listed above should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.

45. IPD Analytics. (2021, April 12). IPD Analytics Pharmacy & Therapeutics Watch List: Provention Bio Faces Delay in FDA Review of Teplizumab for Diabetes . Bay Harbor Islands, FL, USA.
46. IPD Analytics. (2021, March 6). Aducanumab (BIIB037) (Aducanumab). Retrieved from IPDAnalytics.com: https://secure.ipdanalytics.com/User/Pharma/Forecasting2/Forecast/18de83f9-33c7-4e70-a244-a0f3f719015d#section-group-155101
47. IPD Analytics. (2021, March 6). CodeSource. Retrieved from IPDAnalytics.com: https://codesource.ipdanalytics.com/search-results/hcpcs/all/Pembrolizumab
48. IPD Analytics. (2021, April 12). IPD Analytics Pharmacy & Therapeutics Watch List. Bay Harbor Islands, Florida.
49. IPD Analytics. (2021, June 1). IPD Analytics Pharmacy & Therapeutics Watch List | 06.01.2021: BridgeBio's Truseltiq Approved for Advanced or Metastatic Cholangiocarcinoma . Bay Harbor Islands, FL, USA.
50. IPD Analytics. (2021, May 10). IPD Analytics Pharmacy & Therapeutics Watch List: ICER Recommends Low Price for Biogen's Aducanumab After Finding Insufficient Evidence to Support Clinical Benefit . Bay Harbor Islands, FL, USA.
51. IPD Analytics. (2021). New Drug Review: Lumakras (sotorasib). Bay Harbor Islands: IPD Analytics.
52. IPD Analytics. (2021). New Drug Review: Abecma (idecabtagene vicleucel). Bay Harbor Islands, FL: IPD Analytics.
53. IPD Analytics. (2021). NEW DRUG REVIEW: Breyanzi (lisocabtagene maraleucel; liso-cel). Bay Harbor Islands, FL: IPD Analytics.
54. IPD Analytics. (2021). New Drug Review: Jemperli (dostarlimab-gxly). Bay Harbor Islands, FL: IPD Analytics.
55. IPD Analytics. (2021). NOC Code Guide: Abecma IV Infusion for the Treatment of Multiple Myeloma . Bay Harbor Islands, FL: IPD Analytics.
56. IPD Analytics. (2021). NOC Code Guide: Zynlonta (loncastuximab tesirine-lpyl) Injection, for intravenous use. Bay Harbor Islands, FL: IPD Analytics.
57. IPD Analytics. (2021, March 1). Pharmacy and Therapeutics Watch List. Retrieved from IPDAnalytics.com: https://secure.ipdanalytics.com/User/Pharma/RxStrategy/WatchList#high-interest-3021
58. IPD Analytics. (2021). Rx BRIEF: IMMUNOLOGY: Graft-Versus-Host Disease Management and Pipeline. Bay Harbor Islands, FL: IPD Analytics.
59. IPD Analytics. (2021, June 7). TRENDING INDUSTRY & STRATEGY TOPICS: Biogen's Aduhelm Approved for Alzheimer's Disease. Bay Harbor Islands, FL, USA.
60. IPD Analytics. (2021, June 14). TRENDING INDUSTRY & STRATEGY TOPICS: Liminal BioSciences' Ryplazim Approved as a Treatment for Plasminogen Deficiency. Bay Harbor Islands, FL, USA.
61. Johnson & Johnson. (2020, December 3). Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Retrieved from jnj.com: https://www.jnj.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations
62. Junshi Biosciences. (2020, Septembeer 17). Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma. Retrieved from globenewswire.com: https://www.globenewswire.com/news-release/2020/09/17/2095563/0/en/Junshi-Biosciences-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-Toripalimab-for-the-Treatment-of-Soft-Tissue-Sarcoma.html
63. Junshi Biosciences. (2021, January 24). FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma. Retrieved from globenewswire.com: https://www.globenewswire.com/news-release/2021/01/25/2163142/0/en/FDA-Grants-Toripalimab-Fast-Track-Designation-for-Mucosal-Melanoma.html
64. Liminal BioSciences. (2021, June 4). Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh). Retrieved from pipelinereview.com: https://pipelinereview.com/index.php/2021060578360/Proteins-and-Peptides/Liminal-BioSciences-Announces-FDA-Approval-for-its-Biologics-License-Application-for-Ryplazim-plasminogen-human-tvmh.html
65. Matsui H, A. Y. (2020). Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Advances, 3169–3179.
66. May AK, T. V. (2020). Estimating the Impact of Necrotizing Soft Tissue Infections in the United States: Incidence and Re-Admissions. Surgical Infections, https://doi.org/10.1089/sur.2020.099.
67. Medscape. (2021, June 14). plasminogen (Rx). Retrieved from Medscape.com: https://reference.medscape.com/drug/ryplazim-plasminogen-1000182
68. Midha A, D. S. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res, 2892–2911.
69. Min-Ke He, R.-B. L. (2021). Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, Published online March 25. doi: 10.1177/17588359211002720 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010824/.
70. Mirum Pharmaceuticals. (2021, February 1). Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome. Retrieved from drugs.com: https://www.drugs.com/nda/maralixibat_210201.html
71. Murtuza A, B. A. (2019, February). Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Retrieved from cancerres.aacrjournals.org: https://cancerres.aacrjournals.org/content/79/4/689
72. Narendranath Epperla, A. L. (2020). Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. British Journal of Haematology, https://doi.org/10.1111/bjh.16457.
73. National Organization for Rare Disorders. (2021, May 13). Primary Myelofibrosis. Retrieved from rarediseases.org: https://rarediseases.org/rare-diseases/primary-myelofibrosis/#affected-populations
74. National Eczema Association. (2021, May 13). Eczema Stats. Retrieved from nationaleczema.org: https://nationaleczema.org/research/eczema-facts/
75. National Institute of Diabetes and Digestive and Kidney Diseases. (2019, January). Treatment for Alagille Syndrome. Retrieved from niddk.nih.gov: https://www.niddk.nih.gov/health-information/liver-disease/alagille-syndrome/treatment
76. National Organization for Rare Disorders. (2021, May 17). Niemann Pick Disease Type C. Retrieved from rarediseases/org: https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/
77. NCCN. (2020). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer V6.2020. Philadelphia: NCCN.
78. NCCN. (2020). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer V1.2021. Philadelphia: NCCN.
79. NCCN. (2021). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers V3.2021. Philadelphia: NCCN.
80. NCCN. (2021). NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer V4.2021. Philadelphia: NCCN.
81. Nelson, R. (2021, April 20). Tisotumab for Advanced Cervical Cancer Awaiting Approval. Retrieved from medscape.com: https://www.medscape.com/viewarticle/949607#vp_2
82. NINDS. (2020, April 22). Multiple System Atrophy Fact Sheet. Retrieved from www.ninds.nih.gov: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Multiple-System-Atrophy#3145_5
83. NORD. (2020, December 16). Pompe Disease. Retrieved from rarediseases.org: https://rarediseases.org/rare-diseases/pompe-disease/
84. NORD. (2021, March 4). Achondroplasia. Retrieved from rarediseases.org: https://rarediseases.org/rare-diseases/achondroplasia/
85. NORD. (2021, March 6). Niemann Pick Disease Type C. Retrieved from rarediseases.org: https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/
86. Osteoarthritis Action Alliance. (2019, September 19). OA Prevalence & Burden: Osteoarthritis Prevention and Management in Primary Care. Retrieved from oaaction.unc.edu: https://oaaction.unc.edu/wp-content/uploads/sites/623/2019/08/FINAL-OA-Prevalence-and-Burden-final.pdf
87. Pfizer. (2021). Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance. Pfizer.
88. PharmaEssentia Corporation. (2020, June 4). U.S. FDA Accepts PharmaEssentia's Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera. Retrieved from businesswire.com: https://www.businesswire.com/news/home/20200604005204/en/U.S.-FDA-Accepts-PharmaEssentia's-Application-for-Ropeginterferon-Alfa-2b-to-Treat-Polythycemia-Vera
89. Reuters. (2021, April 7). U.S. FDA extends review of Pfizer's experimental skin disease drug. Retrieved from reuters.com: https://www.reuters.com/article/us-pfizer-fda/u-s-fda-extends-review-of-pfizers-experimental-skin-disease-drug-idUSKBN2BU1GZ
90. Rosa, K. (2021, January 26). FDA Grants Fast Track Designation to Toripalimab for Mucosal Melanoma. Retrieved from pharmacytimes.com: https://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-toripalimab-for-mucosal-melanoma
91. Rosa, K. (2021, March 15). FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera. Retrieved from OncLive: https://www.onclive.com/view/fda-issues-complete-response-letter-for-ropeginterferon-alfa-2b-for-polycythemia-vera
92. Rosa, K. (2021, February 18). Vicineum Granted FDA Priority Review for Non–Muscle Invasive Bladder Cancer. Retrieved from pharmacytimes.com: https://www.pharmacytimes.com/news/vicineum-granted-fda-priority-review-for-nonmuscle-invasive-bladder-cancer
93. T Scott Bentley, N. J. (2020). Milliman Research Report: 2020 US organ and tissue transplants: Cost estimates, discussion, and emerging issues. Milliman.
94. Tefferi, A. (2020, September 4). Polycythemia Vera. Retrieved from rarediseases.org: https://rarediseases.org/rare-diseases/polycythemia-vera/
95. Tucker, M. E. (2021, April 16). FDA panel supports islet cell treatment for type 1 diabetes. Retrieved from mdedge.com: https://www.mdedge.com/endocrinology/article/238764/diabetes/fda-panel-supports-islet-cell-treatment-type-1-diabetes

REFERENCES *(continued)*

The above information was assembled from government and clinical resources for knowledge purposes only. Information and drugs were selected by clinicians based on therapy and potential clinical impact without any manufacture affiliations or conflicts of interest. Approval status, dates, and WAC price are subject to variation. This document should not be exclusively used for decision-making purposes. WAC pricing data should be used for benchmarking purposes only. Prices listed above should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.

96. UpToDate. (2021, March 6). Retrieved from UpToDate.com.
97. UpToDate. (2021, March 6). Hydroxyurea (hydroxycarbamide): Drug information. Retrieved from uptodate.com: https://www.uptodate.com/contents/hydroxyurea-hydroxycarbamide-drug-information?search=hydroxyurea&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1
98. WebMD. (2021, May 13). What Is Brittle Diabetes? Retrieved from webmd.com: https://www.webmd.com/diabetes/brittle-diabetes-all-about#1
99. Welldyne. (2021, March 15). WellDyne New Drug to Market Newsletter. Nulibry™ (fosdenopterin) .
100. Wexler, M. (2019, June 20). Rituxan Is Cost-effective for ANCA-associated Vasculitis, Study Says. Retrieved from ancavasculitisnews.com: https://ancavasculitisnews.com/2019/06/20/rituxan-is-cost-effective-for-anca-associated-vasculitis-study-says/
101. Wexler, M. (2021, May 19). FDA Reviewing Efgartigimod as Possible Treatment for Generalized MG. Retrieved from myastheniagravisnews.com: https://myastheniagravisnews.com/news-posts/2021/03/05/fda-review-efgartigimod-argenx-generalized-mg-possible-treatment/
102. Ying Jin, X.-Y. C.-X. (2012). Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 1717-1725.
103. Zhang PL, H. Y. (2016). Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet, 1883-1892.